2023
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.
Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Svoboda J. Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort. Journal Of Clinical Oncology 2023, 41: 7542-7542. DOI: 10.1200/jco.2023.41.16_suppl.7542.Peer-Reviewed Original ResearchProgression-free survivalClassic Hodgkin lymphomaECHELON-1 trialBrentuximab vedotinPeripheral neuropathyNon-trial settingOverall survivalLast followInferior progression-free survivalCox proportional hazards modelExperienced grade 1Grade peripheral neuropathyMulti-institution cohortEffect of discontinuationKaplan-Meier methodAdvanced-stage patientsMultivariable logistic regressionProportional hazards modelHigher initial doseDose holdsCommon toxicitiesMedian followDiscontinuation ratesPerformance statusMedian age
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weekly
2019
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.
Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology 2019, 2019: 252-259. PMID: 31808838, PMCID: PMC6913455, DOI: 10.1182/hematology.2019000030.Peer-Reviewed Original ResearchConceptsFirst-line treatmentClassic Hodgkin lymphomaBrentuximab vedotinNovel therapiesLarge-scale clinical trialsLarge randomized trialsHodgkin lymphoma treatmentRisk of progressionStandard cytotoxic therapiesChemotherapy cyclesDurable remissionsMultiagent chemotherapyMost patientsClinical outcomesRandomized trialsMedical oncologyCytotoxic therapyHodgkin's lymphomaLymphoma treatmentClinical trialsSelect populationIncomplete responseAlkylator chemotherapyChemotherapyAdvanced stage
2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology 2018, 36: jco.18.00122. PMID: 30285558, PMCID: PMC6241679, DOI: 10.1200/jco.18.00122.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioFirst-line settingFirst-line therapyBrentuximab vedotinHodgkin's lymphomaHealth care costsStage IIICare costsDirect health care costsLifetime health care costsOpen-label trialCohort of patientsRisk of progressionUS payer perspectiveMarkov decision-analytic modelCost-effectiveness ratioDecision analytic modelFavourable cost effectivenessCost-effectiveness analysisStandard ABVDClinical outcomesPayer perspectiveParametric survival distributionsIndication-specific pricingCost effectiveness
2017
Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation
Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIncremental cost-effectiveness ratioPrice reductionHealth care costsProbabilistic sensitivity analysesMarkov decision-analytic modelCost-effectiveness ratioIndication-specific pricingLife-time costsCare costsAutologous stem cell transplantationDecision analytic modelStandard discountingQALYBrentuximab vedotinHigher health care costsActive surveillancePricingConsolidative settingConsolidation therapyCostSensitivity analysis